Cargando…

Disruption of ETV6 leads to TWIST1-dependent progression and resistance to epidermal growth factor receptor tyrosine kinase inhibitors in prostate cancer

BACKGROUND: ETS variant gene 6 (ETV6) is a putative tumor suppressor and repressed by epidermal growth factor receptor (EGFR) signaling in prostate cancer. Since EGFR antagonists seem ineffective in castration-resistant prostate cancer (CRPC), we aim to study the role of ETV6 in the development of d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsai, Yuan-Chin, Zeng, Tao, Abou-Kheir, Wassim, Yeh, Hsiu-Lien, Yin, Juan Juan, Lee, Yi-Chao, Chen, Wei-Yu, Liu, Yen-Nien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817720/ https://www.ncbi.nlm.nih.gov/pubmed/29455655 http://dx.doi.org/10.1186/s12943-018-0785-1

Ejemplares similares

MicroRNA-34a regulates WNT/TCF7 signaling and inhibits bone metastasis in Ras-activated prostate cancer
por: Chen, Wei-Yu, et al.
Publicado: (2014)

Pyruvate kinase L/R links metabolism dysfunction to neuroendocrine differentiation of prostate cancer by ZBTB10 deficiency
por: Wen, Yu-Ching, et al.
Publicado: (2022)

Loss of EGFR signaling-regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance
por: Siu, Man Kit, et al.
Publicado: (2014)

Correction: Loss of EGFR signaling-regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance
por: Siu, Man Kit, et al.
Publicado: (2018)

Interplay of Epidermal Growth Factor Receptor and Signal Transducer and Activator of Transcription 3 in Prostate Cancer: Beyond Androgen Receptor Transactivation
por: Lin, Shian-Ren, et al.
Publicado: (2021)

Androgen up-regulation of Twist1 gene expression is mediated by ETV1
por: Khatiwada, Prabesh, et al.
Publicado: (2020)

Novel ETV1 mutation in small cell lung cancer transformation resistant to EGFR tyrosine kinase inhibitors
por: Zhou, Yan, et al.
Publicado: (2021)

Self-Renewing Pten(-/-)TP53(-/-) Protospheres Produce Metastatic Adenocarcinoma Cell Lines with Multipotent Progenitor Activity
por: Abou-Kheir, Wassim, et al.
Publicado: (2011)

Epidermal growth factor receptor tyrosine kinase inhibitors
por: Ranson, M
Publicado: (2004)

An activating mutation of GNB1 is associated with resistance to tyrosine kinase inhibitors in ETV6-ABL1-positive leukemia
por: Zimmermannova, O, et al.
Publicado: (2017)

ZBTB46, SPDEF, and ETV6: Novel Potential Biomarkers and Therapeutic Targets in Castration-Resistant Prostate Cancer
por: Fararjeh, AbdulFattah Salah, et al.
Publicado: (2019)

Therapeutic impact of epidermal growth factor receptor tyrosine kinase inhibitor with various treatment combinations for advanced lung adenocarcinoma
por: Chen, Ying-Yi, et al.
Publicado: (2023)

Myeloid/lymphoid neoplasms with eosinophilia/basophilia and ETV6-ABL1 fusion: cell-of-origin and response to tyrosine kinase inhibition
por: Yao, Jinjuan, et al.
Publicado: (2020)

Androgen receptor regulates SRC expression through microRNA-203
por: Siu, Man Kit, et al.
Publicado: (2016)

An ATPase with a twist: A unique mechanism underlies the activity of the bacterial tyrosine kinase, Wzc
por: Hajredini, Fatlum, et al.
Publicado: (2021)

MicroRNAs as clinical tools for diagnosis, prognosis, and therapy in prostate cancer
por: Ghamlouche, Fatima, et al.
Publicado: (2023)

ETV3 and ETV6 enable monocyte differentiation into dendritic cells by repressing macrophage fate commitment
por: Villar, Javiera, et al.
Publicado: (2022)

Conditional Deletion of Activating Rearranged During Transfection Receptor Tyrosine Kinase Leads to Impairment of Photoreceptor Ribbon Synapses and Disrupted Visual Function in Mice
por: Peng, Wei-Hao, et al.
Publicado: (2021)

IGFBP7 Drives Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Lung Cancer
por: Wu, Shang-Gin, et al.
Publicado: (2019)

Structured and disordered regions cooperatively mediate DNA-binding autoinhibition of ETS factors ETV1, ETV4 and ETV5
por: Currie, Simon L., et al.
Publicado: (2017)

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?
por: Banno, Eri, et al.
Publicado: (2016)

Epidermal Growth Factor Is Essential for the Maintenance of Novel Prostate Epithelial Cells Isolated From Patient-Derived Organoids
por: Cheaito, Katia, et al.
Publicado: (2020)

The Transcription Factor ETV5 Mediates BRAFV600E-Induced Proliferation and TWIST1 Expression in Papillary Thyroid Cancer Cells()
por: Puli, Oorvashi Roy, et al.
Publicado: (2018)

Robust differentiation of human pluripotent stem cells into endothelial cells via temporal modulation of ETV2 with modified mRNA
por: Wang, Kai, et al.
Publicado: (2020)

HDAC9 structural variants disrupting TWIST1 transcriptional regulation lead to craniofacial and limb malformations
por: Hirsch, Naama, et al.
Publicado: (2022)

Crosstalk between COVID-19 and prostate cancer
por: Bahmad, Hisham F., et al.
Publicado: (2020)

Recruitment of epidermal growth factor receptors into coated pits requires their activated tyrosine kinase
Publicado: (1995)

Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Chang, Youjin, et al.
Publicado: (2013)

Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance
por: Heydt, Carina, et al.
Publicado: (2018)

Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors: are we actually ready?
por: Tabbò, Fabrizio, et al.
Publicado: (2020)

Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab
por: Chikaishi, Yasuhiro, et al.
Publicado: (2020)

Etv4 and Etv5 are required downstream of GDNF and Ret for kidney branching morphogenesis
por: Lu, Benson, et al.
Publicado: (2009)

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
por: Chang, Shih-Chieh, et al.
Publicado: (2011)

Sustained Activation of Lyn Tyrosine Kinase In Vivo Leads to Autoimmunity
por: Hibbs, Margaret L., et al.
Publicado: (2002)

Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Chen, Yu-Mu, et al.
Publicado: (2015)

Treating with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Accompanying Lower Incidence of Second Primary Cancers
por: Chou, Wen-Ru, et al.
Publicado: (2022)

Prostate Cancer and Aspirin Use: Synopsis of the Proposed Molecular Mechanisms
por: Bilani, Nadeem, et al.
Publicado: (2017)

Should Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Be Continued beyond Progressive Disease?
por: Kim, Young Hak, et al.
Publicado: (2011)

Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors
por: Chen, Justin A., et al.
Publicado: (2020)

Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer
por: Abunada, Aya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p4mh12ssofb63u43l5dlf5jvnc